Ashwagandha Targets Multiple Aging Hallmarks with Measurable Clinical Results

The global demographic shift toward older populations has intensified pressure on healthcare systems and spotlighted the need for safe, accessible geroprotective agents. Ashwagandha (Withania somnifera), a cornerstone of Ayurvedic medicine classified as a Rasayana or rejuvenator, has accumulated a substantial modern scientific evidence base. This 2025 comprehensive review by Vittal and Vinciguerra, published in Biogerontology, synthesizes preclinical and clinical data to evaluate whether ashwagandha can meaningfully extend healthspan by targeting the biological drivers of aging simultaneously.

At the molecular level, ashwagandha's primary bioactive compounds—withanolides including withaferin A, withanone, and withanolide A—operate through several complementary mechanisms. Withanone activates heat-shock proteins that act as molecular chaperones preventing protein aggregation, while also enhancing the ubiquitin-proteasome system responsible for clearing toxic misfolded proteins—directly addressing the proteostasis failure central to Alzheimer's and Parkinson's disease pathology. Separately, withanolides upregulate the Nrf2 antioxidant pathway, a master regulator of redox balance that shields mitochondria from oxidative damage and sustains cellular energy production. The herb also modulates the AMPK and SIRT1 longevity-signaling axes, mimicking some cellular effects of caloric restriction without dietary limitation. In human cell lines, ashwagandha root extract increased telomerase activity by approximately 45%, suggesting direct support for chromosomal integrity and cellular longevity.

Preclinical organism models corroborate these molecular findings. In C. elegans, root extract extended mean lifespan by approximately 20% and improved late-life healthspan metrics including pharyngeal pumping and locomotor activity. In Drosophila melanogaster, withaferin A protected against age-related physiological decline and extended lifespan, establishing cross-species geroprotective relevance. These model organism data provide biological plausibility for the human trial outcomes reviewed.

In human clinical trials, the physical performance data are among the most robust. A landmark resistance-training RCT found that 600 mg/day of ashwagandha produced a ~46 kg increase in bench press one-rep max versus ~26 kg for placebo, and an 8.6 cm² gain in arm muscle area versus 5.3 cm² for placebo—directly addressing sarcopenia, one of aging's most debilitating features. Twelve weeks of supplementation at 300 mg twice daily significantly enhanced VO2 max by 13.6% versus 9.7% in controls, a clinically meaningful difference given that cardiorespiratory fitness is among the strongest predictors of longevity. In overweight aging men, ashwagandha increased testosterone by 14.7% and the anti-aging hormone DHEA-S by 18%. In a trial of healthy older adults aged 65–80, sleep quality and mental alertness upon waking improved significantly. An 8-week RCT in perimenopausal women showed meaningful reductions in Menopause Rating Scale scores alongside hormonal improvements. A topical 8% extract formulation applied for 60 days improved skin hydration by 20.66% versus 9.5% for placebo and elasticity by 16.34% versus 3.73%, with physician-assessed reductions in wrinkles and pore size.

Neurological and cognitive benefits are also documented. Clinical trials demonstrated improvements in memory and information-processing speed, particularly in adults with mild cognitive impairment. Preclinical models of Alzheimer's and Parkinson's disease show neuroprotective potential via the proteostasis and anti-inflammatory mechanisms described above. Anti-inflammatory effects—modulating immune responses and reducing C-reactive protein—address inflammaging, the chronic low-grade inflammation increasingly recognized as a central driver of age-related multimorbidity. The authors conclude that while the multi-target evidence base is compelling, large-scale, long-term, standardized-extract trials are essential to confirm ashwagandha's role in healthy aging across diverse global populations.